Viekira Pak
MSD’s Zepatier approval could spell end of Gilead’s Hep C dominance, says analyst
February 10, 2016Sales and Marketing AbbVie, Drug pricing, Gilead Sciences, MSD, Solvadi, Viekira Pak, harvoni, hepatitis C
The introduction of MSDs’ recently FDA-approved drug Zepatier (elbasvir/grazoprevir) to the hepatitis C treatment space will shake up a market …
AbbVie posts strong Q4 results
February 1, 2016Sales and Marketing AbbVie, Humira, Viekira Pak
AbbVie managed to meet or beat analysts’ expectations in its Q4 financial results report, with extremely strong Humira sales contributing …
New regulatory submissions for AbbVie and Novo Nordisk
December 4, 2015Medical Communications AbbVie, EMA, FDA, Novo Nordisk, Viekira Pak, insulin aspart
AbbVie and Novo Nordisk have submitted new drug applications to the US FDA and European Medicines Agency (EMA) respectively. The …
AbbVie hep C drug gets priority review in Japan
April 16, 2015Sales and Marketing AbbVie, EC, EU, Europe, Exviera, FDA, Japan, Viekira Pak, Viekirax, hepatitis C, ombitasvir/paritaprevir/ritonavir
AbbVie’s combination hepatitis C treatment looks set to be approved in yet another country after being granted priority review in …
AbbVie Hep C combo pill ready for Europe
January 16, 2015Medical Communications AbbVie, Exviera, FDA, HIV, Viekira Pak, Viekirax, harvoni, hep C, sovaldi
The European Commission has approved AbbVie’s Viekirax and Exviera for the treatment of chronic hepatitis C (HCV). Viekirax (ombitasvir/paritaprevir/ritonavir) and …
Abbvie Hep C drug gains FDA approval
December 22, 2014Sales and Marketing AbbVie, FDA, Gilead, Viekira Pak, dasabuvir, harvoni, hepatitis, hepatits C
Abbvie has gained sign-off for its rival treatment to challenge Gilead’s dominance of the growing market for new hepatitis C …
Latest content
FibroFind appoints Lee Borthwick as CEO
